A detailed history of Kcs Wealth Advisory transactions in Abb Vie Inc. stock. As of the latest transaction made, Kcs Wealth Advisory holds 1,475 shares of ABBV stock, worth $265,500. This represents 0.1% of its overall portfolio holdings.

Number of Shares
1,475
Previous 1,567 5.87%
Holding current value
$265,500
Previous $211,000 3.79%
% of portfolio
0.1%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 02, 2023

SELL
$133.59 - $154.65 $12,290 - $14,227
-92 Reduced 5.87%
1,475 $219,000
Q2 2023

Jul 17, 2023

BUY
$132.51 - $164.9 $11,263 - $14,016
85 Added 5.74%
1,567 $211,000
Q1 2023

Apr 17, 2023

SELL
$144.61 - $166.54 $4,338 - $4,996
-30 Reduced 1.98%
1,482 $236,000
Q3 2022

Oct 21, 2022

BUY
$134.21 - $153.93 $1,476 - $1,693
11 Added 0.73%
1,512 $203,000
Q2 2022

Jul 22, 2022

BUY
$137.62 - $174.96 $6,881 - $8,748
50 Added 3.45%
1,501 $230,000
Q1 2022

Apr 13, 2022

SELL
$131.98 - $163.75 $13,197 - $16,375
-100 Reduced 6.45%
1,451 $235,000
Q4 2021

Jan 26, 2022

BUY
$107.43 - $135.93 $166,623 - $210,827
1,551 New
1,551 $210,000
Q4 2019

Jan 15, 2020

SELL
$72.13 - $90.25 $150,895 - $188,803
-2,092 Closed
0 $0
Q3 2019

Oct 29, 2019

BUY
$62.98 - $75.72 $131,754 - $158,406
2,092 New
2,092 $158,000
Q4 2018

Jan 17, 2019

SELL
$77.85 - $96.01 $167,455 - $206,517
-2,151 Closed
0 $0
Q3 2018

Nov 06, 2018

SELL
$88.91 - $98.84 $114,249 - $127,009
-1,285 Reduced 37.4%
2,151 $203,000
Q2 2018

Aug 07, 2018

SELL
$89.78 - $106.23 $18,853 - $22,308
-210 Reduced 5.76%
3,436 $318,000
Q1 2018

May 04, 2018

SELL
$92.01 - $123.21 $45,176 - $60,496
-491 Reduced 11.87%
3,646 $345,000
Q4 2017

Jan 12, 2018

BUY
$89.56 - $98.21 $370,509 - $406,294
4,137
4,137 $400,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Kcs Wealth Advisory Portfolio

Follow Kcs Wealth Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kcs Wealth Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Kcs Wealth Advisory with notifications on news.